Rezultati - David Fabrizio
- Showing 1 - 20 results of 32
- Go to Next Page
-
1
-
2
Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current Evidence od Samuel J. Klempner, David Fabrizio, Shalmali Bane, Marcia Reinhart, Tim Peoples, Siraj M. Ali, Ethan S. Sokol, Garrett M. Frampton, Alexa B. Schrock, Rachel Anhorn, Prasanth Reddy
Izdano 2019Revisão -
3
DRAGON: A Member of the Repulsive Guidance Molecule-Related Family of Neuronal- and Muscle-Expressed Membrane Proteins Is Regulated by DRG11 and Has Neuronal Adhesive Properties od Tarek A. Samad, Ashok Srinivasan, Laurie A. Karchewski, Sung‐Jin Jeong, Jason Campagna, Ru‐Rong Ji, David Fabrizio, Ying Zhang, Herbert Y. Lin, Esther Bell, Clifford J. Woolf
Izdano 2004Artigo -
4
Prevalence of established and emerging biomarkers of immune checkpoint inhibitor response in advanced hepatocellular carcinoma od Celina Ang, Samuel J. Klempner, Siraj M. Ali, Russell W. Madison, Jeffrey S. Ross, Eric A. Severson, David Fabrizio, Aaron M. Goodman, Razelle Kurzrock, James Suh, Sherri Z. Millis
Izdano 2019Artigo -
5
Prevalence of<i>PDL1</i>Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors od Aaron M. Goodman, David Piccioni, Shumei Kato, Amélie Boichard, Huan‐You Wang, Garrett M. Frampton, Scott M. Lippman, Caitlin Connelly, David Fabrizio, Vincent A. Miller, Jason K. Sicklick, Razelle Kurzrock
Izdano 2018Artigo -
6
Prevalence of High Tumor Mutational Burden and Association With Survival in Patients With Less Common Solid Tumors od Changxia Shao, Gerald Li, Lingkang Huang, Scott K. Pruitt, Emily Castellanos, Garrett M. Frampton, Kenneth R. Carson, Tamara Snow, Gaurav Singal, David Fabrizio, Brian M. Alexander, Fan Jin, Wei Zhou
Izdano 2020Artigo -
7
Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population od C. Benedikt Westphalen, Matthew Krebs, C. Le Tourneau, Ethan Sokol, Sophia L. Maund, Timothy R. Wilson, Dexter X. Jin, Justin Y. Newberg, David Fabrizio, L. Véronèse, M. Thomas, Filippo de Braud
Izdano 2021Artigo -
8
High Tumor Mutational Burden Correlates with Longer Survival in Immunotherapy-Naïve Patients with Diverse Cancers od Paul Riviere, Aaron M. Goodman, Ryosuke Okamura, Donald A. Barkauskas, Theresa J. Whitchurch, Suzanna Lee, Noor Khalid, Rachel Collier, Manvita Mareboina, Garrett M. Frampton, David Fabrizio, Andrew B. Sharabi, Shumei Kato, Razelle Kurzrock
Izdano 2020Artigo -
9
DRAGON, a Bone Morphogenetic Protein Co-receptor od Tarek A. Samad, Anuradha Rebbapragada, Esther Bell, Ying E. Zhang, Yisrael Sidis, Sung‐Jin Jeong, Jason Campagna, Stephen Perusini, David Fabrizio, Alan L. Schneyer, Herbert Y. Lin, Ali H. Brivanlou, Liliana Attisano, Clifford J. Woolf
Izdano 2005Artigo -
10
Blood-based biomarkers for cancer immunotherapy: Tumor mutational burden in blood (bTMB) is associated with improved atezolizumab (atezo) efficacy in 2L+ NSCLC (POPLAR and OAK) od David R. Gandara, Marcin Kowanetz, Tony Mok, Achim Rittmeyer, Louis Fehrenbacher, David Fabrizio, Geoff Otto, Christine M. Malboeuf, Daniel S. Lieber, Sarah Paul, Lukas C. Amler, Todd Riehl, Erica Schleifman, Craig Cummings, P. Hegde, Wei Zou, Anna Sandler, M. Ballinger, David S. Shames
Izdano 2017Artigo -
11
Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in <i>ERBB2</i> and <i>ERBB3</i> od Jeffrey S. Ross, Marwan Fakih, Siraj M. Ali, Julia A. Elvin, Alexa B. Schrock, James Suh, Jo‐Anne Vergilio, Shakti Ramkissoon, Eric A. Severson, Sugganth Daniel, David Fabrizio, Garrett M. Frampton, James Sun, Vincent A. Miller, Philip J. Stephens, Laurie M. Gay
Izdano 2018Artigo -
12
Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition od David Fabrizio, Thomas J. George, Richard F. Dunne, Garrett M. Frampton, James Sun, Kyle Gowen, Mark Kennedy, Joel Greenbowe, Alexa B. Schrock, Aram F. Hezel, Jeffrey S. Ross, P. J. Stephens, Siraj M. Ali, Vincent A. Miller, Marwan Fakih, Samuel J. Klempner
Izdano 2018Artigo -
13
A Novel Next-Generation Sequencing Approach to Detecting Microsatellite Instability and Pan-Tumor Characterization of 1000 Microsatellite Instability–High Cases in 67,000 Patient S... od Sally E. Trabucco, Kyle Gowen, Sophia L. Maund, Eric M. Sanford, David Fabrizio, Michael J. Hall, Evgeny Yakirevich, Jeffrey P. Gregg, Phil Stephens, Garrett M. Frampton, Priti S. Hegde, Vincent A. Miller, Jeffrey S. Ross, Ryan J. Hartmaier, Shih-Min A. Huang, James Sun
Izdano 2019Artigo -
14
Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial od Edward S. Kim, Vamsidhar Velcheti, Tarek Mekhail, Cindy Yun, Sarah M. Shagan, Sylvia Hu, Young Kwang Chae, Ticiana Leal, Jonathan E. Dowell, Michaela L. Tsai, Christopher Dakhil, Philip J. Stella, Yanling Jin, David S. Shames, Erica Schleifman, David Fabrizio, See Phan, Mark A. Socinski
Izdano 2022Artigo -
15
Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors od Jessica Lee, Smruthy Sivakumar, Alexa B. Schrock, Russell W. Madison, David Fabrizio, Ole Gjoerup, Jeffrey S. Ross, Garrett M. Frampton, Pavel Napalkov, Meagan Montesion, Jennifer L. Schutzman, Xin Ye, Priti S. Hegde, Misako Nagasaka, Geoffrey R. Oxnard, Ethan Sokol, Sai‐Hong Ignatius Ou, Zhen Shi
Izdano 2022Artigo -
16
A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer od Zoe J. Assaf, Wei Zou, Alexander D. Fine, Mark A. Socinski, Amanda Young, Doron Lipson, Jonathan F. Freidin, Mark Kennedy, Eliana Polisecki, Makoto Nishio, David Fabrizio, Geoffrey R. Oxnard, Craig Cummings, Anja Rode, Martin Reck, Namrata S. Patil, Mark Lee, David S. Shames, Katja Schulze
Izdano 2023Artigo -
17
Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate Cancer od Christopher J. Sweeney, Russell Petry, Chang Xu, Merrida Childress, Jie He, David Fabrizio, Ole Gjoerup, Samantha Morley, Timothy Catlett, Zoe J. Assaf, Kobe Yuen, Matthew Wongchenko, Kalpit Shah, Pratyush Gupta, Priti Hegde, Lincoln W. Pasquina, Sanjeev Mariathasan, Ryon P. Graf, Thomas Powles
Izdano 2024Artigo -
18
Comprehensive genomic profiles of metastatic and relapsed salivary gland carcinomas are associated with tumor type and reveal new routes to targeted therapies od Jeffrey S. Ross, Laurie M. Gay, K. Wang, Jo‐Anne Vergilio, James Suh, Shakti Ramkissoon, Hilary Somerset, Jennifer M. Johnson, Jeffery S. Russell, Siraj M. Ali, Alexa B. Schrock, David Fabrizio, Garrett M. Frampton, V.A. Miller, Philip J. Stephens, Julia A. Elvin, Daniel W. Bowles
Izdano 2017Artigo -
19
Final efficacy results from B-F1RST, a prospective phase II trial evaluating blood-based tumour mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L no... od Mark A. Socinski, Vamsidhar Velcheti, Tarek Mekhail, Y.K. Chae, Ticiana Leal, J.E. Dowell, Ming-Hung Tsai, Christopher Dakhil, Philip J. Stella, Vincent K. Shen, Sylvia Hu, S.M. Paul, David S. Shames, Erica Schleifman, David Fabrizio, Michaeł Nowicki, C. Yun, S. Phan, E.S. Kim
Izdano 2019Artigo -
20
A Novel HRD Signature Is Predictive of FOLFIRINOX Benefit in Metastatic Pancreatic Cancer od Kuei‐Ting Chen, Russell W. Madison, Jay A. Moore, Dexter X. Jin, Zoë Fleischmann, Justin Y. Newberg, Alexa B. Schrock, Neeru Bhardwaj, Katherine T Lofgren, Jie He, Garrett M. Frampton, Priti Hegde, David Fabrizio, Michael J. Pishvaian, Ericka M. Ebot, Aatur D. Singhi, Ethan Sokol
Izdano 2023Artigo
Iskalna orodja:
Sorodne teme
Cancer
Medicine
Biology
Internal medicine
Oncology
Cancer research
Gene
Genetics
Immunotherapy
Allele
Microsatellite
Microsatellite instability
Biochemistry
Biomarker
Lung cancer
KRAS
Mutation
Chemistry
Colorectal cancer
Computational biology
Atezolizumab
Chemotherapy
Exome
Exome sequencing
Immune checkpoint
Receptor
Adenocarcinoma
Bioinformatics
Cell biology
Clinical trial